Major hospital networks are incorporating targeted high-throughput genomic sequencing directly into emergency triage and early-stage oncology protocols as per-sample sequencing costs decline.
Diagnostic Velocity
Turnaround times for panel-based genomic assays have decreased from weeks to under 48 hours, enabling clinical teams to select targeted therapies before secondary disease progression occurs.
Reimbursement Shift
Health insurers are expanding coverage codes for multi-gene panel diagnostics, citing long-term treatment cost reductions achieved through avoiding non-responsive therapeutic regimens.